查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年神經遺傳學測試市場預測：按類型、最終用戶和地區分類的全球分析
市場調查報告書
商品編碼
1383476

2030 年神經遺傳學測試市場預測：按類型、最終用戶和地區分類的全球分析

Neurogenetic Testing Market Forecasts to 2030 - Global Analysis By Type (Microarray Analysis, Whole-Exome Sequencing, Multiplex Ligation Dependent Probe Amplification, Polymerase Chain Reaction Tests and Other Types), By End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球神經遺傳學檢測市場規模將達6.167億美元，預測期內年複合成長率為12.1%，預計到2030年將達到13.721億美元。

神經遺傳學測試涉及檢查個體的基因組成，以識別與神經系統疾病相關的特定遺傳變異。其應用包括診斷神經系統疾病、評估風險因素和指導個體化治療計劃，從而實現更有針對性和更有效的醫療保健干涉措施。

根據世界衛生組織報告，歐洲地區神經系統疾病負擔佔全球的11.2%，其次是西太平洋地區，佔10%。

神經系統疾病盛行率上升

人們對阿茲海默症、帕金森氏症和各種神經發育障礙等疾病的認知和了解不斷增加，推動了對準確和早期基因檢測的需求不斷成長。神經遺傳學檢測的進步為了解這些疾病的遺傳傾向和危險因素提供了一個窗口，有助於早期診斷和有針對性的治療計劃。隨著這些疾病受到更多關注和醫學認知的進步，對有效的神經遺傳學檢測的需求將使我們能夠客製化干涉措施，實現更好的管理，並應對這些挑戰，包括神經系統疾病的發病和進展。或延遲

與測試相關的成本高且可近性有限

基因檢測方法的複雜性，加上對專門設備和專業知識的需求，導致檢測急劇上升，使許多人無法承擔這些服務。此外，先進的神經遺傳學檢測的機會有限，特別是在貧困和偏遠地區，限制了這些重要診斷工具的可用性。因此，在獲得尖端醫療保健解決方案方面的差距仍然存在，使許多人無法從神經系統疾病的早期診斷、個體化治療和風險評估中受益。

研發進度

基因檢測技術的不斷進步，加上對神經系統疾病遺傳基礎的深入了解，正在推動更複雜、更準確和更全面的檢測方法的發展。這項進步不僅擴大了可進行基因檢測的疾病範圍，也提高了診斷的準確性和可靠性。此外，它還促進了新的遺傳標記和潛在治療標靶的發現，促進了神經病學個人化醫療的發展。

基因檢測方法的複雜性

基因檢測技術通常涉及難以實施和理解的複雜過程，例如定序、微陣列分析和基因突變的解釋。對高度專業化的設備、訓練有素的專業人員和廣泛的生物資訊分析的需求可能會導致高昂的營運成本和有限的高級測試機會。此外，這些測試的複雜性可能會導致錯誤、資料誤解或誤診，從而影響其可靠性和準確性。此外，基因檢測的複雜性可能會阻礙醫療保健提供者和患者接受這些診斷工具，特別是在技術基礎設施和醫療保健專業知識有限的地區。

COVID-19 的影響：

COVID-19大流行對市場產生了重大影響，帶來了挑戰和機會。儘管供應鏈和臨床業務最初的中斷影響了檢測的機會，但了解病毒對神經系統影響的緊迫性加速了神經遺傳學的研究和開發。遠端醫療和遠距測試已成為人們關注的焦點，使患者的訪問和診斷變得更加容易。這段時期，神經系統疾病基因檢測的重要性被強調，刺激了檢測技術的投資和創新。儘管最初遇到了挫折，但這場大流行促使人們取得進展，並讓人們更加認知到神經遺傳學測試在醫療保健中所發揮的重要作用，並有可能重塑市場的未來格局。

聚合酶鍊式反應（PCR）檢測領域預計在預測期內規模最大

聚合酶鏈反應（PCR）檢測佔有很大的市場佔有率。 PCR 擴增 DNA 片段的能力可以幫助檢測與亨廷頓氏症和帕金森氏症等疾病相關的突變。其高特異性和靈敏度能夠準確分析遺傳標記，這對於早期診斷和疾病監測至關重要。 PCR 的作用延伸到神經病學、藥物開發和個人化醫療的研究，促進對疾病遺傳基礎的理解取得進展。作為基本工具，PCR 檢測不斷革新神經遺傳學檢測，並培養塑造研究和臨床方法的見解。

預計醫院領域在預測期內的年複合成長率最高。

在預測期內，醫院的年複合成長率最高。醫院提供先進的檢測設施，實現全面的基因篩檢，並協助識別神經遺傳疾病。這些機構正在將檢測整合到診斷途徑中，促進疾病的早期發現和個體化治療策略。該醫院還透過匯集遺傳學家、神經學家和其他專家來提供全面的護理，為正在進行的研究做出貢獻，並引入尖端的測試方法，從而推進神經遺傳學測試。它還作為跨學科合作的中心，大大塑造了景觀。

佔比最大的地區：

北美佔據重要地位，預計在預測期內將佔據最大佔有率。該地區是大型生物技術和製藥公司的所在地，促進創新並推動尖端檢測方法的發展。在神經系統疾病盛行率較高且醫療保健系統積極的北美，神經遺傳學檢測已廣泛應用於臨床和研究領域。該區域市場的特點是強力的法律規範、學術界和工業界之間的戰略合作夥伴關係以及對個人化醫療的日益關注，使北美在神經遺傳學檢測領域處於領先地位的地位正在鞏固。

複合年複合成長率最高的地區：

亞太地區的年複合成長率最高。該地區人口眾多且多樣化，神經系統疾病負擔沉重，增加了對先進診斷解決方案的需求。此外，新興經濟體的存在和政府的支持措施正在促進亞太地區工業界和研究機構之間的合作，擴大檢測範圍，並不斷發展客製化的神經系統疾病診斷和管理方法。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球神經遺傳學測試市場：按類型

  • 微陣列分析
  • 全外EXOME定序（WES）
  • 多重連接依賴性探針擴增 (MLPA)
  • 聚合酶連鎖反應（PCR）測試
  • 其他類型

第6章 全球神經遺傳學測試市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 研究機構
  • 診斷實驗室
  • 其他最終用戶

第7章 全球神經遺傳學測試市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第8章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第9章 公司簡介

  • Invitae Corporation
  • Ambry Genetics
  • PerkinElmer
  • GeneDx
  • Centogene
  • Blueprint Genetics
  • Genomic Health（Exact Sciences）
  • Fulgent Genetics
  • QIAGEN
  • Baylor Genetics
Product Code: SMRC24324

According to Stratistics MRC, the Global Neurogenetic Testing Market is accounted for $616.7 million in 2023 and is expected to reach $1372.1 million by 2030 growing at a CAGR of 12.1% during the forecast period. Neurogenetic testing involves examining an individual's genetic makeup to identify specific genetic variations associated with neurological conditions. Its uses include diagnosing neurological disorders, assessing risk factors and guiding personalized treatment plans, leading to more targeted and effective healthcare interventions.

According to a WHO report, the European region contributes 11.2% of global burden of neurological disorder followed by Western Pacific region with 10%.

Market Dynamics:

Driver:

Rising prevalence of neurological disorders

The growing recognition and understanding of conditions like Alzheimer's, Parkinson's, and various neurodevelopmental disorders prompt a heightened demand for accurate and early genetic testing. Advances in neurogenetic testing provide a window into the genetic predispositions and risk factors for these conditions, facilitating early diagnosis and precise treatment planning. As these disorders gain prominence and medical understanding evolves, the need for effective neurogenetic testing becomes pivotal in tailoring interventions, enabling better management, and potentially averting or delaying the onset and progression of these challenging neurological conditions.

Restraint:

High costs associated with testing and limited accessibility

The complex nature of genetic testing methods, coupled with the need for specialized equipment and expertise, contributes to elevated testing costs, making these services unaffordable for many individuals. Additionally, limited accessibility to advanced neurogenetic tests, especially in underprivileged or remote regions, restricts the reach of these crucial diagnostic tools. As a result, disparities in access to cutting-edge healthcare solutions persist, preventing many from benefiting from early diagnosis, personalized treatment, and risk assessment for neurological conditions.

Opportunity:

Increasing research and development

Ongoing advancements in genetic testing technologies, coupled with deeper insights into the genetic underpinnings of neurological disorders, drive the development of more sophisticated, accurate, and comprehensive testing methods. This progress not only expands the scope of disorders that can be genetically tested but also enhances the precision and reliability of diagnostics. Moreover, it fuels the discovery of novel genetic markers and potential therapeutic targets, fostering the evolution of personalized medicine in neurology.

Threat:

The complexity of genetic testing methods

Genetic testing techniques, which often involve intricate processes like sequencing, microarray analysis, and interpretation of genetic variations, can be challenging to implement and comprehend. The need for highly specialized equipment, skilled professionals, and extensive bioinformatics analysis can lead to high operational costs, limiting accessibility to advanced testing. Additionally, the intricate nature of these tests may result in errors, data misinterpretation, or misdiagnoses, impacting their reliability and precision. Furthermore, the complexity of genetic testing can deter healthcare providers and patients from embracing these diagnostic tools, particularly in regions with limited technological infrastructure or healthcare expertise.

COVID-19 Impact:

The COVID-19 pandemic significantly impacted the market, driving both challenges and opportunities. While initial disruptions in supply chains and clinical operations affected testing accessibility, the urgency to understand neurological implications of the virus accelerated research and development in neurogenetics. Telehealth and remote testing gained prominence, facilitating patient access and diagnosis. This period underscored the importance of genetic testing in neurological disorders, prompting increased investment and innovation in testing technologies. Despite initial setbacks, the pandemic spurred advancements and a broader recognition of the critical role neurogenetic testing plays in healthcare, potentially reshaping the market's future landscape.

The polymerase chain reaction (PCR) tests segment is expected to be the largest during the forecast period

The polymerase chain reaction (PCR) test has a significant share in the market. PCR's ability to amplify DNA segments aids in detecting mutations linked to disorders like Huntington's disease or Parkinson's. Its high specificity and sensitivity empower accurate analysis of genetic markers, crucial in early diagnosis and disease monitoring. PCR's role extends to research, drug development, and personalized medicine within neurology, driving advancements in understanding the genetic basis of conditions. As a foundational tool, PCR tests continue to revolutionize neurogenetic testing, fostering insights that shape both research and clinical approaches.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospital has the highest CAGR within the market over the forecast period. They offer access to sophisticated testing facilities, allowing comprehensive genetic screenings, aiding in the identification of neurogenetic disorders. These institutions integrate testing into their diagnostic pathways, facilitating early disease detection and personalized treatment strategies. Hospitals also serve as centers for multidisciplinary collaboration, bringing together geneticists, neurologists, and other specialists to provide holistic care, contributing to ongoing research, and implementing cutting-edge testing methodologies, thereby significantly shaping the landscape of neurogenetic testing.

Region with largest share:

North America holds a significant position and expected to hold a largest share over the forecast period. The region houses leading biotech and pharmaceutical companies, fostering innovation and driving the development of cutting-edge testing methodologies. With a high prevalence of neurological disorders and a proactive healthcare system, North America witnesses extensive adoption of neurogenetic testing across clinical and research domains. The market in this region is characterized by a strong regulatory framework, strategic collaborations between academic institutions and industry, and a growing emphasis on personalized medicine, solidifying North America's position at the forefront of neurogenetic testing advancements.

Region with highest CAGR:

The Asia Pacific region witnessed highest CAGR in the market. With a large and diverse population, this region encounters a notable burden of neurological disorders, propelling the need for advanced diagnostic solutions. Furthermore, the presence of emerging economies and supportive government initiatives fosters collaborations between industry and research institutions, paving the way for expanded accessibility to testing and fueling the evolution of tailored approaches for diagnosing and managing neurological conditions in the Asia Pacific.

Key players in the market

Some of the key players in Neurogenetic Testing Market include: Invitae Corporation, Ambry Genetics, PerkinElmer, GeneDx, Centogene, Blueprint Genetics, Genomic Health (Exact Sciences), Fulgent Genetics, QIAGEN and Baylor Genetics.

Key Developments:

In April 2023, Ambry Genetics and LifeStrands Genomics had collaborated to provide clinical genetic testing services in Singapore. Together, they have been chosen to support the Clinical Implementation Pilots (CIPs) for Phase II of Singapore's National Precision Medicine (NPM) programme through an open tender commissioned by Precision Health Research, Singapore (PRECISE) - the central entity implementing NPM.

In April 2023, Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that it will present new data highlighting the company's novel technology and approaches to early cancer detection at the American Association for Cancer Research® (AACR) Annual Meeting 2023 in Orlando, Florida.

In August 2022, PerkinElmer has signed an agreement with private equity firm New Mountain Capital for the sale of its Applied, Food and Enterprise Services businesses for $2.45bn in cash to allow the company to focus on its high-margin Life Science and Diagnostics businesses.

Types Covered:

  • Microarray Analysis
  • Whole-Exome Sequencing (WES)
  • Multiplex Ligation Dependent Probe Amplification (MLPA)
  • Polymerase Chain Reaction (PCR) Tests
  • Other Types

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Diagnostics Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neurogenetic Testing Market, By Type

  • 5.1 Introduction
  • 5.2 Microarray Analysis
  • 5.3 Whole-Exome Sequencing (WES)
  • 5.4 Multiplex Ligation Dependent Probe Amplification (MLPA)
  • 5.5 Polymerase Chain Reaction (PCR) Tests
  • 5.6 Other Types

6 Global Neurogenetic Testing Market, By End User

  • 6.1 Introduction
  • 6.2 Hospitals
  • 6.3 Specialty Clinics
  • 6.4 Research Institutes
  • 6.5 Diagnostics Laboratories
  • 6.6 Other End Users

7 Global Neurogenetic Testing Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Invitae Corporation
  • 9.2 Ambry Genetics
  • 9.3 PerkinElmer
  • 9.4 GeneDx
  • 9.5 Centogene
  • 9.6 Blueprint Genetics
  • 9.7 Genomic Health (Exact Sciences)
  • 9.8 Fulgent Genetics
  • 9.9 QIAGEN
  • 9.10 Baylor Genetics

List of Tables

  • Table 1 Global Neurogenetic Testing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 4 Global Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 5 Global Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 6 Global Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 7 Global Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 9 Global Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 10 Global Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 11 Global Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 12 Global Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 13 Global Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 14 North America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 15 North America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 16 North America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 17 North America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 18 North America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 19 North America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 20 North America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 21 North America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 22 North America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 North America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 24 North America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 25 North America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 26 North America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 27 Europe Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 Europe Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 29 Europe Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 30 Europe Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 31 Europe Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 32 Europe Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 33 Europe Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 34 Europe Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 Europe Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 36 Europe Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 37 Europe Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 38 Europe Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 39 Europe Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 40 Asia Pacific Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 41 Asia Pacific Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 42 Asia Pacific Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 43 Asia Pacific Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 44 Asia Pacific Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 45 Asia Pacific Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 46 Asia Pacific Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 47 Asia Pacific Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 48 Asia Pacific Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 49 Asia Pacific Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 50 Asia Pacific Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 51 Asia Pacific Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 52 Asia Pacific Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 53 South America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 South America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 55 South America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 56 South America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 57 South America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 58 South America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 59 South America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 60 South America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 61 South America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 62 South America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 63 South America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 64 South America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 65 South America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 66 Middle East & Africa Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 67 Middle East & Africa Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 68 Middle East & Africa Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 69 Middle East & Africa Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 70 Middle East & Africa Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 71 Middle East & Africa Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 72 Middle East & Africa Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 73 Middle East & Africa Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 74 Middle East & Africa Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 75 Middle East & Africa Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 76 Middle East & Africa Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 77 Middle East & Africa Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 78 Middle East & Africa Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)